Vertex Pharma (VRTX) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $530.76 -4.05%
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
WMK, FACO, SEB, More
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
WMK, FACO, SEB, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $0.35, $0.06 better than the analyst estimate of $0.29. Revenue for the quarter came in at $458.71 versus the consensus estimate of $453.4 million.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Latham Group, Inc. (SWIM) Misses Q3 EPS by 5c ; Offers Guidance
- Ashland (ASH) Misses Q4 EPS by 16c ; Offers Guidance
- Procore (PCOR) Tops Q3 EPS by 5c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
